Medical technology solutions company Haemonetics Corporation (NYSE:HAE) announced on Thursday that it has obtained US Food and Drug Administration (FDA) 510(k) clearance for its TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge.
This expansion enhances TEG 6s testing capabilities for fully heparinized patients in adult cardiovascular surgeries/procedures and liver transplantation settings, across laboratories and point-of-care. Rapid assessment of a patient's hemostasis status is crucial for optimal clinical outcomes and blood product management.
Haemonetics' cartridge-based TEG 6s system offers comprehensive coagulation profiles swiftly, surpassing conventional tests with actionable results. Supported by TEG Manager software, the TEG 6s analyzer provides real-time results viewing and customizable alert messages for interpretation guidance.
The release of the new Global Hemostasis-HN cartridge for TEG 6s system is scheduled in the upcoming months, following successful 510(k) clearance backed by extensive clinical trials involving 335 patients and establishment of normal reference ranges using 164 healthy volunteers, totaling over 5,500 clinical data points.
AstraZeneca completes acquisition of Amolyt Pharma
CureLab Oncology names new CMO
Tempus announces receipt of FDA clearance for AI-based AFib risk detection
Revelation Biosciences' Phase 1 study shows promising results for TLR4 agonist Gemini
Smartcella adds new board members
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Haemonetics' TEG 6s hemostasis cartridge gains FDA clearance
Polymedco's PATHFAST hs-cTnI-II test receives US FDA clearance
Gilgamesh Pharmaceuticals receives multi-year USD14m grant from NIDA
Advanced Medical Solutions Group plc proposes GBP120.8m acquisition of Peters Surgical
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes